Literature DB >> 9891528

Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer.

M Dong1, Y Nio, K J Guo, K Tamura, Y L Tian, Y T Dong.   

Abstract

The expression of epidermal growth factor (EGF) and its receptor (EGFR) was studied immunohistochemically in fifty-seven Chinese patients with primary invasive ductal carcinoma (IDC) of the pancreas. The frequency of expression of EGF and EGFR was 73.7% and 68.4%, respectively. The frequency of their co-expression was 61.4%. No significant relationships were seen between the expression of EGF and its receptor and the patients' age, gender, site of the tumor, stage, and grade. Positive co-expression of EGF and EGFR was significantly associated with the poor prognosis. The median survival of the EGF(-)EGFR(-) group for 17.2 months was longer than that of the EGF(+)EGFR(+) group for 9.7 months (p = 0.02), as well as that of the other groups of EGR(+)EGFR(-), EGF(-)EGFR(+), and EGF(+)EGFR(+) for 9.9 month (p = 0.03). These results suggested that EGF and EGFR were frequently expressed in Chinese patients with IDC of the pancreas. Their co-expression may be a useful prognostic indicator for pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9891528

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

Review 1.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  New targeted therapies in pancreatic cancer.

Authors:  Andrada Seicean; Livia Petrusel; Radu Seicean
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

3.  Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.

Authors:  Joanne W Chiu; Hilda Wong; Roland Leung; Roberta Pang; Tan-To Cheung; Sheung-Tat Fan; Ronnie Poon; Thomas Yau
Journal:  Oncologist       Date:  2014-08-12

4.  Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.

Authors:  Shadan Ali; Sanjeev Banerjee; Jacqueline M Schaffert; Bassel F El-Rayes; Philip A Philip; Fazlul H Sarkar
Journal:  J Cell Biochem       Date:  2010-05       Impact factor: 4.429

5.  IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.

Authors:  Kevin Chu Foy; Megan J Miller; Jay Overholser; Siobhan M Donnelly; Rita Nahta; Pravin Tp Kaumaya
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

6.  Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma.

Authors:  Amit Mahipal; Mary J Mcdonald; Agnieszka Witkiewicz; Brian I Carr
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

7.  EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.

Authors:  Seok Ju Park; Mi Jin Gu; Dong Shik Lee; Sung Soo Yun; Hong Jin Kim; Joon Hyuk Choi
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

8.  Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.

Authors:  Randall J Kimple; Angelina V Vaseva; Adrienne D Cox; Kathryn M Baerman; Benjamin F Calvo; Joel E Tepper; Janiel M Shields; Carolyn I Sartor
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

9.  Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src.

Authors:  Soumya Jaganathan; Peibin Yue; James Turkson
Journal:  J Pharmacol Exp Ther       Date:  2010-01-25       Impact factor: 4.030

10.  Small molecule tyrosine kinase inhibitors in pancreatic cancer.

Authors:  Sachin Gupta; Bassel F El-Rayes
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.